J
Q1 2026 13F Highlights: 5 Top Funds in 5 Minutes
15 May was the SEC 13F deadline for Q1 2026. Five top managers I think are worth a read. Here's what changed, in plain SG-investor language.
Teva Pharmaceutical Industries
TEVA----
Teva Pharmaceutical Industries (TEVA)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the Unite...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Teva Pharmaceutical Industries Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$40.9032.75%
Forecast & RatingStrong buy
12analysts
- Strong buy58.33%
- Buy41.67%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- ZeroHedge · 2 days ago, 08:45 AM
UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring Winners
- Fiercepharma · Jul 21 at 08:08 AM
J&J’s Tremfya remains on top in Q2 pharma ad spending league
- Tip Ranks · Jul 20 at 06:27 AM
Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
- Global Report · Jul 19 at 04:13 AM
Cross-Sector Metrics Diverge as Stellantis Surges and Energy Micro-Caps Face Restructuring
- Market Beat · Jul 12 at 05:02 PM
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study
- Market Beat · Jul 12 at 11:33 AM
Sumitomo Mitsui Trust Group Inc. Has $65.48 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA
Posts
View MoreBullish vs. Bearish — Last 3 Months
1.4k followers · 0 opinions
▲Bullish50%
50%Bearish▼